Blar i forfatter "Strøm, Hans Henrik"
-
Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group
Strøm, Hans Henrik; Bremnes, Roy M.; Sundstrøm, Stein Harald; Helbekkmo, Nina; Fløtten, Øystein; Aasebø, Ulf (Journal article; Tidsskriftartikkel; Peer reviewed, 2013-08-20)Background: The palliative role of chemoradiation in the treatment of patients with locally advanced, inoperable non-small-cell lung cancer stage III and negative prognostic factors remains unresolved.<p> <p>Methods: Patients not eligible for curative radiotherapy were randomised to receive either chemoradiation or chemotherapy alone. Four courses of intravenous carboplatin on day 1 and oral ... -
The Conrad Study - A randomised, multicenter phase III trial of combination chemotherapy ± thoracic radiotherapy in the treatment of patients in poor condition with stage III non-small cell lung cancer not eligible for radical therapy
Strøm, Hans Henrik (Doctoral thesis; Doktorgradsavhandling, 2014-12-10)The thesis constitutes the collected report on an RCT the candidate has conducted on behalf of the Norwegian Lung Cancer Study Group. In addition to three scientific articles published in international peer-reviewed journal, it consists of texts on the background, the choice of methods and material, as well as results and discussion of the treatment regimens that have been studied in the trial. ... -
How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced NoneSmall Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial
Strøm, Hans Henrik; Bremnes, Roy M.; Sundstrøm, Stein Harald; Helbekkmo, Nina; Aasebø, Ulf (Journal article; Tidsskriftartikkel; Peer reviewed, 2015-05)In a phase III trial of patients with unresectable stage III nonesmall-cell lung cancer and a poor prognosis, palliative concurrent chemoradiotherapy (CRT) provided a significantly better outcome than chemotherapy alone, except among performance status 2 patients. The results of the present exploratory subgroup analysis indicate that elderly patients with poor prognosis can also experience ... -
Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: A subset analysis from a randomized clinical phase III trial
Strøm, Hans Henrik; Bremnes, Roy M.; Sundstrøm, Stein Harald; Helbekkmo, Nina; Aasebø, Ulf (Journal article; Tidsskriftartikkel; Peer reviewed, 2015-11-20)Introduction: Poor prognosis patients with bulky stage III locally advanced non–small-cell lung cancer may not be offered concurrent chemoradiotherapy (CRT). Following a phase III trial concerning the effect of palliative CRT in inoperable poor prognosis patients, this analysis was performed to explore how tumor size influenced survival and health-related quality of life (HRQOL).<p> <p>Methods: ...